Semaglutide and Pregnancy: Safety Data and What to Do If You Get Pregnant on GLP-1

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Semaglutide is not recommended during pregnancy due to limited human data and animal study concerns; discontinue treatment at least two months before planned conception and consult a healthcare provider immediately if pregnancy occurs while on medication.

# Semaglutide and Pregnancy: Safety Data and What to Do If You Get Pregnant on GLP-1

Semaglutide, a potent GLP-1 receptor agonist, has transformed the management of type 2 diabetes and obesity. However, its use in women of reproductive age raises critical questions regarding pregnancy safety. Given the physiological changes during gestation and the potential for fetal exposure, understanding the current safety data and clinical recommendations is paramount for both patients and healthcare providers.

Current Safety Data: Limited Human Evidence, Animal Concerns

Human Data: There is very limited human data on semaglutide use during pregnancy. Clinical trials for semaglutide have typically excluded pregnant women, and post-marketing data are still accumulating. The available information from pregnancy registries (e.g., Novo Nordisk"s GLP-1 RA Pregnancy Registry) is observational and does not provide sufficient evidence to establish drug-associated risks.

Animal Studies: Animal reproduction studies have shown adverse developmental outcomes with semaglutide. In pregnant rats, rabbits, and cynomolgus monkeys, exposure to semaglutide during organogenesis resulted in embryo-fetal mortality, structural abnormalities, and altered fetal growth at clinically relevant exposures. While animal study findings do not always translate directly to humans, they raise significant concerns and underscore the need for caution.

Mechanism of Concern: GLP-1 receptors are expressed in various fetal tissues, suggesting a potential for direct effects on fetal development. Additionally, semaglutide"s mechanism of action, which includes appetite suppression and weight loss, could theoretically lead to inadequate maternal weight gain or nutrient deficiencies during pregnancy, although this is speculative.

Recommendations for Planned Pregnancy

Given the lack of robust human safety data and the concerns from animal studies, the current recommendation is to discontinue semaglutide at least two months prior to a planned conception. This "washout" period is based on the drug"s half-life and aims to ensure that semaglutide levels are negligible in the body before pregnancy is established. Effective contraception is strongly advised for women of reproductive potential during semaglutide treatment.

What to Do If You Get Pregnant While on Semaglutide

If a patient becomes pregnant while taking semaglutide, immediate action is required:

  • Discontinue Semaglutide Immediately: The medication should be stopped as soon as pregnancy is confirmed.
  • Contact Healthcare Provider: The patient should promptly inform their prescribing physician or healthcare provider about the pregnancy. They will assess the situation, discuss potential risks, and adjust the treatment plan.
  • Enroll in a Pregnancy Registry: Healthcare providers should encourage patients to enroll in a pregnancy registry (e.g., the GLP-1 RA Pregnancy Registry) to help monitor pregnancy outcomes and contribute to a better understanding of the drug"s safety profile in humans. This data is crucial for future guidance.
  • Comprehensive Prenatal Care: Ensure the patient receives comprehensive prenatal care, including early and regular monitoring for any potential complications.
  • Discuss Alternative Management: For women with diabetes or obesity, alternative management strategies will be necessary during pregnancy. This may include insulin therapy for diabetes, nutritional counseling, and close monitoring of maternal weight gain and fetal growth.

    • Contraception Considerations

    For women of reproductive potential, robust contraception is a critical component of semaglutide treatment. Given the recommendation for a two-month washout period, patients should use highly effective birth control methods consistently throughout their treatment course if they are not planning pregnancy.

    Future Research

    Ongoing research and the collection of real-world data through pregnancy registries are vital to better understand the safety of semaglutide and other GLP-1RAs during pregnancy. As more data become available, clinical guidelines may evolve. Until then, a cautious approach prioritizing maternal and fetal safety is warranted.

    Conclusion

    While semaglutide offers significant benefits for diabetes and weight management, its use during pregnancy is currently not recommended due to limited human safety data and concerning animal study findings. Women of reproductive potential should use effective contraception and discontinue semaglutide at least two months before planned conception. If pregnancy occurs while on treatment, immediate discontinuation and consultation with a healthcare provider are essential to ensure the best possible outcomes for both mother and baby.